Singula is a superior predictor of PFS and OS in GBM patients compared to PPT. Singula can identify non-responders to PPT and provide alternative therapy selections.
A randomized trial in glioblastoma patients with methylated-MGMT (m-MGMT) found an improvement in median survival of 16.7 months for combination therapy with temozolomide (TMZ) and lomustine, however the approach remains controversial and relatively under-utilized. Therefore, we sought to determine whether comprehensive genomic analysis can predict which patients would derive large, intermediate, or negligible benefits from the combination compared to single agent chemotherapy.
The Cellworks Singula Therapeutic Response Index (TRI) has been developed to assist clinicians and GBM patients in choosing between competing therapeutic options. In contrast to approaches that consider single aberrations, which often yield limited benefit, Cellworks utilizes an individual patient’s next generation sequencing results and a mechanistic multi-omics biology model, the Cellworks Omics Biology Model (CBM), to biosimulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells.
CPA shows that m-MGMT is an excellent biomarker for determining the likelihood of benefit from TMZ and lomustine, with the caveat that CBM identifies 18% could be spared from TMZ exposure and would benefit from Lomustine alone.
Precision medicine has been most successful in targeting single mutations, but personalized medicine using broader genomic tumor profiles for individual patients is less well-developed. We evaluate a genomics-informed computational biology model (CBM) to predict outcomes from standard treatments and to suggest novel therapy recommendations in glioblastoma (GBM).
Tumor metabolism is the hallmark of cancer cells. Cancer cells utilize different nutrient sources to drive the metabolic pathways to sustain tumor growth. Glucose (Glu) and Glutamine (Gln) are the primary nutrient sources on which cancer cells thrive. Developing precision diet based on patient’s molecular characteristics can help treat the cancer with dietary modulations along with traditional approaches.
Statins are potent competitive inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR), a rate-limiting enzyme in the mevalonate pathway (cholesterol synthesis or isoprenoid pathway;
Background: The unique signature of a patient’s tumor implies that a one-size-fits-all treatment approach will likely fail. This necessitates a rationally designed personalized therapeutic approach employing N=1 segmentation.